Immunoprecise Antibodies (IPA)

• Market cap: $125M
• 1 day: -2.17%
• 5 days: 3.85%
• 1 month: 33.66%
• 3 months: 405.62%
• 6 months: 655.88%
• Year to date: 500.00%
• 1 year: 240.35%
• 5 years: -83.10%
• 10 years: -83.10%
• Sector: Healthcare
• Industry: Biotechnology

About: ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.

Employees: 102

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,613% more call options, than puts

Call options by funds: $137K | Put options by funds: $8K

136% more capital invested

Capital invested by funds: $1.48M [Q1] → $3.49M (+$2.01M) [Q2]

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

2.86% more ownership

Funds ownership: 8.59% [Q1] → 11.45% (+2.86%) [Q2]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

4% less funds holding

Funds holding: 24 [Q1] → 23 (-1) [Q2]